AMRN:NSD-Amarin Corporation plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.68

Change

-0.17 (-4.42)%

Market Cap

USD 1.50B

Volume

0.01B

Average Target Price

USD 9.55 (+159.39%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.76 (-1.41%)

USD69.70B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

-6.32 (-1.11%)

USD60.80B 21.90 16.92
SGEN Seattle Genetics, Inc

-2.68 (-1.47%)

USD31.66B N/A N/A
MRNA Moderna, Inc

-1.56 (-2.27%)

USD27.12B N/A N/A
RPRX Royalty Pharma plc

+0.06 (+0.14%)

USD25.33B 35.72 9.73
GMAB Genmab A/S

-2.15 (-5.63%)

USD25.18B 27.12 3.06
ALXN Alexion Pharmaceuticals, Inc

-2.08 (-1.82%)

USD25.10B 30.43 27.52
BGNE BeiGene, Ltd

+5.88 (+2.19%)

USD24.63B N/A N/A
IMMU Immunomedics, Inc

+0.12 (+0.14%)

USD19.66B N/A N/A
INCY Incyte Corporation

-0.96 (-1.10%)

USD19.01B 47.64 35.20

ETFs Containing AMRN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -82.84% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.84% 2% F 1% F
Trailing 12 Months  
Capital Gain -77.17% 4% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.17% 4% F 3% F
Trailing 5 Years  
Capital Gain 64.29% 81% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.29% 80% B- 72% C-
Average Annual (5 Year Horizon)  
Capital Gain 124.50% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.50% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 201.59% N/A N/A N/A N/A
Risk Adjusted Return 61.76% N/A N/A N/A N/A
Market Capitalization 1.50B 82% B- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.74 68% D+ 44% F
Price / Cash Flow Ratio -159.77 99% A+ 97% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -3.33% 93% A 49% F
Return on Invested Capital -5.49% 88% B+ 36% F
Return on Assets -1.81% 93% A 38% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.17 50% F 40% F
Short Percent N/A N/A N/A N/A N/A
Beta 2.66 7% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.